Filed: 11/6/2025ACC: 0001553936-25-000013
📋 What this filing means
TYBOURNE CAPITAL MANAGEMENT (HK) LTD filed this quarterly 13F‑HR report disclosing 4 equity positions with a total reported market value of $30.93M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
4
Positions
$30.93M
Total AUM (reported)
6.85M
Total Shares
Allocation by class
COM SHS$12.10M39.1%
COM NEW$11.80M38.1%
COM$7.03M22.7%
Portfolio Concentration
Top 3$29.48M95.3%
4–10$1.45M4.7%
Top 3 weight
95.3%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 6.85M
Sole
Full voting authority
6.85M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole4
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings4
Rows:
TAYSHA GENE THERAPIES INC (TSHA US)
SOLEShares3.70M
TypeSH
Market value$12.10M
39.11%
Sole
3.70M
Shared
0.00
None
0.00
FORTE BIOSCIENCES INC (FBRX US)
SOLEShares786.65K
TypeSH
Market value$11.80M
38.15%
Sole
786.65K
Shared
0.00
None
0.00
ALUMIS INC (ALMS US)
SOLEShares1.40M
TypeSH
Market value$5.58M
18.05%
Sole
1.40M
Shared
0.00
None
0.00
ZENTALIS PHARMACEUTICALS INC (ZNTL US)
SOLEShares961.49K
TypeSH
Market value$1.45M
4.69%
Sole
961.49K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
TAYSHA GENE THERAPIES INC (TSHA US)SOLE | COM SHS | 3.70M | SH | $12.10M 39.11% | 3.70M | 0.00 | 0.00 |
FORTE BIOSCIENCES INC (FBRX US)SOLE | COM NEW | 786.65K | SH | $11.80M 38.15% | 786.65K | 0.00 | 0.00 |
ALUMIS INC (ALMS US)SOLE | COM | 1.40M | SH | $5.58M 18.05% | 1.40M | 0.00 | 0.00 |
ZENTALIS PHARMACEUTICALS INC (ZNTL US)SOLE | COM | 961.49K | SH | $1.45M 4.69% | 961.49K | 0.00 | 0.00 |